[go: up one dir, main page]

HK1001835A1 - Therapeutic agents for use in the treatment of parkinson's disease - Google Patents

Therapeutic agents for use in the treatment of parkinson's disease

Info

Publication number
HK1001835A1
HK1001835A1 HK98100812A HK98100812A HK1001835A1 HK 1001835 A1 HK1001835 A1 HK 1001835A1 HK 98100812 A HK98100812 A HK 98100812A HK 98100812 A HK98100812 A HK 98100812A HK 1001835 A1 HK1001835 A1 HK 1001835A1
Authority
HK
Hong Kong
Prior art keywords
group
parkinson
disease
treatment
therapeutic agents
Prior art date
Application number
HK98100812A
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishil
Shunji Ichikawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of HK1001835A1 publication Critical patent/HK1001835A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HK98100812A 1992-04-08 1998-02-04 Therapeutic agents for use in the treatment of parkinson's disease HK1001835A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8711592 1992-04-08

Publications (1)

Publication Number Publication Date
HK1001835A1 true HK1001835A1 (en) 1998-07-10

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98100812A HK1001835A1 (en) 1992-04-08 1998-02-04 Therapeutic agents for use in the treatment of parkinson's disease

Country Status (11)

Country Link
EP (1) EP0565377B1 (es)
JP (1) JP2613352B2 (es)
AT (1) ATE161723T1 (es)
BR (1) BR1100636A (es)
CA (1) CA2093403C (es)
DE (1) DE69316067T2 (es)
DK (1) DK0565377T3 (es)
ES (1) ES2112386T3 (es)
GR (1) GR3026233T3 (es)
HK (1) HK1001835A1 (es)
NO (1) NO303265B1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585464A4 (en) * 1992-02-19 1994-03-21 Yukio Ishida HIGHLY WATER ABSORBING RICE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF.
DE69331843T2 (de) * 1992-07-08 2002-09-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine-Derivate als Antidepressiva
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE69430747T2 (de) * 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
AU1823895A (en) * 1994-02-23 1995-09-11 Kyowa Hakko Kogyo Co. Ltd. Xanthine derivative
CA2262578A1 (en) * 1996-08-07 1998-02-12 Kunio Ito Fat emulsion containing xanthine derivative
US6727259B2 (en) 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
RU2367442C2 (ru) 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
ES2532479T3 (es) 2004-01-28 2015-03-27 Kyowa Hakko Kirin Co., Ltd. Agentes para el tratamiento de la migraña
AU2006230447A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
EP1928414A2 (en) * 2005-04-22 2008-06-11 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 a2a 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN112409360B (zh) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 杂芳基乙烯基黄嘌呤衍生物及其用途
WO2021093701A1 (en) * 2019-11-11 2021-05-20 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA929519A (en) * 1969-07-30 1973-07-03 Schweiss Dieter Xanthine compounds and means for obtaining the same
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
WO1992006976A1 (fr) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine

Also Published As

Publication number Publication date
CA2093403A1 (en) 1993-10-09
BR1100636A (pt) 2000-04-18
NO931317L (no) 1993-10-11
ES2112386T3 (es) 1998-04-01
CA2093403C (en) 1999-08-10
JPH0616559A (ja) 1994-01-25
NO931317D0 (no) 1993-04-06
GR3026233T3 (en) 1998-05-29
DE69316067D1 (de) 1998-02-12
JP2613352B2 (ja) 1997-05-28
EP0565377A1 (en) 1993-10-13
DK0565377T3 (da) 1998-03-16
EP0565377B1 (en) 1998-01-07
DE69316067T2 (de) 1998-07-02
ATE161723T1 (de) 1998-01-15
NO303265B1 (no) 1998-06-22

Similar Documents

Publication Publication Date Title
GR3026233T3 (en) Therapeutic agents for use in the treatment of Parkinson's Disease
ES2141137T3 (es) Agentes terapeuticos para la enfermedad de parkinson.
HUT68856A (en) Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
ATE232531T1 (de) Heterobizyklische derivate
DE69418704D1 (de) Anthranilsäure derivate
MX9800577A (es) Derivados de 4,5-diaril oxazol.
RU92004336A (ru) Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты
NO940737L (es)
ZA86262B (en) Therapeutic agents
ATE145906T1 (de) Benzamid-derivate
FI941958A (fi) 2-heterosyklinenetyyliamiinijohdannaiset ja niiden käyttö lääkkeinä
DE69110217D1 (de) Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen.
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
FR2694557B1 (fr) Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100408